# Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

> **NCT06454383** · PHASE1 · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 19 (estimated)

## Conditions studied

- Advanced Pancreatic Adenocarcinoma
- Stage III Pancreatic Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8
- Unresectable Pancreatic Ductal Adenocarcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Cholestyramine
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Diagnostic Imaging
- **DRUG:** Gemcitabine
- **DRUG:** Leflunomide
- **PROCEDURE:** Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT06454383
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-13
- **Primary completion:** 2026-11-13
- **Final completion:** 2026-11-13
- **Target enrollment:** 19 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06454383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06454383, "Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06454383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*